Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
Date:3/8/2010

d Laboratory Services net revenues, Manufacturing Services net revenues, operating income, adjusted EBITDA, gross margins, and other trends) and outlook for 2011 (including expected growth in China-based laboratory services, improving margins and meaningful revenues for various service areas) and the factors driving each; planned capital expenditure and investment levels, and the anticipated benefits of those efforts and the planned expansion of our service offerings and areas of related revenue growth.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, continued uncertainty in the global economy and the pressures being felt by our customers and pharmaceutical industry consolidation may adversely impact our business and the trends for outsourced R&D and manufacturing for longer than expected or more severely than expected; we may be unable to successfully make our planned investments and capital expenditures on a timely basis, these investments may not yield the desired results, and we may need to modify the nature and level of our investments and capital expenditures; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and may be unable to successfully expand our capabilities to meet client needs. In
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
2. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
3. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
4. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
5. WuXi PharmaTech Announces Second-Quarter 2009 Results
6. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
7. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
8. WuXi PharmaTech Receives Award from BASF
9. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
10. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
11. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and synthetic processes prefer to settle into equilibriuma ... is within the realm of non-equilibrium conditions where ... in energy and phases, such as temperature fluctuations, ... humans to regulate their body temperature, airplanes to ... activity. , But even though these conditions ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... balances – 4 steps – One Recommendation: the web-based ... narrows down the mass of product choices to a ... , First, select the working environment, then enter the ... define the accuracy – it’s really that simple. Specifying ... to models that fit best with the customer’s industry ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 As ... manage numerous projects in the MENA region during 2014 ... have a preferred provider agreement with DZS to manage ... MENA region,” said Global VP of R&D and President ... has developed excellent operational practices with a focus on ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... 2011 Palatin Technologies, Inc. (NYSE Amex: PTN ) ... of shares of its common stock and warrants to purchase common ... market conditions and there can be no assurance as to whether ... actual size or terms of the offering. Roth Capital ...
... GREAT NECK, N.Y., Feb. 23, 2011 Scarguard Labs, ... of scars, psoriasis and other dermatological problems through the ... delivery system, announced today that they have received approval ... consumers throughout Canada. "We are very pleased ...
... Quanterix Corporation, a single molecule diagnostics company providing ... in vitro diagnostics markets, today announced the online publication ... Si ngle Mo lecule A rray (SiMoA™) ... straightforward measurement.  The article appears in the journal ...
Cached Biology Technology:Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 3Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability 2
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... release is available in German . ... to recognize and respond to threats to health, and ... detailed understanding of the mechanism underlying immunologic memory, however, ... have converged to support the hypothesis that the persistence ... cells with stem-cell-like potential. Until now, there was no ...
Breaking Biology News(10 mins):Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3
... 2013 The Damon Runyon Cancer Research Foundation ... its spring 2013 Clinical Investigator Award Committee review. ... are outstanding early career physician-scientists conducting patient-oriented cancer ... of the nation,s leading scientists and clinicians. ...
... other conditions caused by malfunctions in the body,s nerve ... treat. The problem is that one medicine may help ... which drugs will work with individual patients may be ... seemingly identical neurons can behave the same even though ...
... discovered a mechanism that triggers chronic inflammation in ... today in Nature Immunology , suggest a ... the way to a new class of therapies ... diseases without crippling the immune system. Alzheimer,s, atherosclerosis ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 2Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 3Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 4Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 5Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 6Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 7Nerve cells can work in different ways with same result 2Researchers discover new way to block inflammation 2
... Intended Use: Vision Mount is formulated for covering tissue ... soluble OR alcohol insoluble end products. , ... ... chromogens such as Fast-Red or AEC that require an aqueous ...
... potent Rnase free Ribonuclease Inhibitor ... broad range of temperatures and ... not inhibit SP6, T7, or ... M-MLV reverse transcriptase or Taq ...
... kit, 110 to 220 V, enables ... doubles flow rates and valve capacity ... kit includes the Maximizer base unit, ... tubing kit, system cable 30, and ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: